Clinical Trial

Daily Tadalafil as Adjunctive Therapy Versus Monotherapy for PDE5 Inhibitor-Resistant Erectile Dysfunction

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This randomized trial will compare daily tadalafil 5 mg as adjunct therapy versus monotherapy in men with on-demand PDE5 inhibitor-resistant erectile dysfunction. The study will evaluate changes in erectile function, treatment satisfaction, partner satisfaction, and safety over 12 weeks.
Protocol Amendment History 2 changes
critical Enrollment reopened 2026-08-15
critical Trial status changed: Not Yet Recruiting → Active, Not Recruiting 2026-08-13
Trial Details
NCT Number NCT07753720
Lead Sponsor Al-Azhar University
Conditions Erectile Dysfunction, Tadalafil
Enrollment 260 participants
Start Date 2026-08-13
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-14